CA9 and urinary bladder carcinoma: On the contrary, radiopharmaceuticals targeting biomarkers that are frequently overexpressed in urothelial cancers, such as Nectin-4 [31,32], anhydrase carbonic IX (CAIX) [33,34], urokinase plasminogen activator receptor (uPAR) [35], or trophoblast cell surface antigen 2 (Trop-2) [36], hold great promise for imaging bladder cancer with enhanced contrast and higher specificity.